Households exposed to COVID-19 now have an oral drug specifically cleared to prevent infection after contact with a sick ...

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...

REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. The Food and Drug Administration (FDA) has ...

In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).

Heavy is the head that wears the COVID-19 crown. Late last week, Pfizer revealed its antiviral Paxlovid fell short in a post-exposure protection trial. Still, in the pill’s quest to reach as many ...

Human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) entails the prompt administration of antiretroviral agents following potential exposure to prevent viral acquisition. Clinical ...

Detailed price information for Shionogi & CO Ltd (SGIOF) from The Globe and Mail including charting and trades.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Following the June update that allowed for a lower dose ...